Effect of the consumption of a probiotic strain on the prevention of post-operative recurrence in Crohn's disease

NCT ID NCT01698970

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 21, 2026 · Last updated Oct 22, 2026 · Updated 1 time

Summary

A double-blind, multicentre, stratified by centre, randomised, parallel study with two groups of adult patients operated on for Crohn's disease, to determine if oral ingestion of probiotics could prevent the appearance of Crohn's disease recurrent endoscopic ileo-colonic lesions 12 months after surgery. Patients will consume 900 mg/day of active product (N=56) or control product (N=56) during one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

122 people

The number who actually took part.

Start date

Feb 2004

Finished

Mar 2010

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male/female at least 18 years old * Diagnosis of Crohn's disease defined by the criteria usually adopted (Gower-Rousseau, 1994) * Crohn's disease mainly limited to the terminal ileum and/or the ascending and transverse colon * Diagnosis of Crohn's disease in agreement with surgical specimen analysis * Patient having given its written consent to take part in the study * Complete resection of all main macroscopic ileo-colonic lesions, as shown by inspection at surgery * To have an ileo-colic resection (right, transverse, left) with an anastomosis that can be inspected by endoscopy * Ability to start oral nutrition and therefore the consumption of the study product within 21 days of surgery * Patient receiving no antibiotics at the beginning of the product consumption Exclusion Criteria: * One or more intestinal resection during the 5 last years before the last surgery * Presence of any severe additional disease * For female patient : pregnancy or breast feeding * For pre-menopausal female patient : no effective contraceptive methods used (combined oestrogen-progestogen pill or Intrauterine Device) * Patient currently in an exclusion period following participation in another clinical trial * Patient in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the patient * Significant presence of Crohn's disease in other intestinal tracts * Small bowel cumulative resection exceeding 1 meter * Patient with ileostomy * Subtotal colectomy with ileo-rectal anastomosis * Severe post-operative septic complications (fistula, peritonitis), leading to administration of more than 15 days of post-operative antibiotherapy) * Intake of unauthorised treatments (mesalazine, olsalazine or sulfasalazine, 5-Aminosalicylates (5-ASA) or 4-Aminosalicylates (4-ASA)) ; corticoïds and immunosuppressors) after surgery except corticoids which will have to be stopped within 6 weeks after surgery according to standardised stepwise dose reductions * Patient under artificial nutrition * Subject with a loss of personal liberty, by administrative or judicial decision, or major with a legal guardian

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Huriez - Service des maladies de l'appareil digestif et de la nutrition

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.